Add Trial
Sign In

A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer

Study Type Treatment
Sponsor Name Pfizer
Tumor Site NSCLC - Non Small Cell Lung Cancer
Disease Stage Stage IV
Clinical Status Advanced Disease 1st Line
Phase Phase III
Intervention / Treatment Lorlatinib versus Crizotinib
Research Site Montreal, QC, McGill University Health Center
Investigator Dre Vera Hirsch
Coordinator Nicolas Raby
Telephone Number +1 (514) 934-4411
Fax Number
Study Start Date February 14, 2017
Study End Date
Trial Status Recruiting


Working Hours :

Now Closed UTC - 4
  • MondayDay Off
  • TuesdayDay Off
  • WednesdayDay Off
  • ThursdayDay Off
  • FridayDay Off
  • SaturdayDay Off
  • SundayDay Off

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: B7461006

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Account details will be confirmed via email.

Reset Your Password